Organization_____ Bldg./Room_____
U. S. DEPARTMENT OF COMMERCE
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS

U.S. OFFICIAL MAIL
PENALTY FOR
PRIVATE USE $300
PITNEY BOWES
02 1A
0004204479
$ 01.29⁰
NOV 25 2005
MAILED FROM ZIP CODE 22314

AN EQUAL OPPORTUNITY EMPLOYER



A-2

KNOB201 9411113022 1804 16 12/05/05
FORWARD TIME EXP RTN TO SEND
:KNOBBE MARTENS OLSON & BEAR
1 SANSOME ST FL 35
SAN FRANCISCO CA 94104-4436

RETURN TO SENDER

RECEIVED
DEC 13 2005
USPTO MAIL CENTER

GFW

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/066,500	02/01/2002	Avi J. Ashkenazi	P3130R1C7	5350

7590 11/25/2005

Ginger R. Dreger
Knobbe Martens Olson & Bear
Suite 1150
201 California Street
San Francisco, CA 94111

EXAMINER	
CHERNYSHEV, OLGA N	

ART UNIT	PAPER NUMBER
1649	

DATE MAILED: 11/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/066,500	ASHKENAZI ET AL.	
	Examiner	Art Unit	
	Olga N. Chernyshev	1649	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *20 October 2005*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *40-47,50-52 and 56-72* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *40-47,50-52 and 56-72* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date *10/20/5*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 20, 2005 has been entered.

Response to Amendment

2. Claims 40-47, 50-52 and 56-72 are under examination in the instant office action.

3. The Text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

4. Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.

5. Applicant's arguments filed on October 20, 2005 have been fully considered but they are not deemed to be persuasive for the reasons set forth below.

Claim Rejections - 35 USC § 101

6. Claims 40-47, 50-52 and 56-72 stand rejected under 35 U.S.C. 101 because the claimed invention is drawn to an invention with no apparent or disclosed specific and substantial credible utility for those reasons of record in previous office actions of record.

At pages 3-4 of the Response, Applicant first reviews case law pertinent to the utility requirements and refers to the appropriate section of MPEP as well as to Utility Examination

Guidelines. Applicant further refers to case law to support the statement that in order to satisfy the utility requirement, "utility need not be proved to a statistical certainty" (pages 4-6, specifically at page 4). Applicant summarizes the evidence for the asserted utility of the claimed polypeptides as being "useful to treat tumors by affecting neovascularization and for the stimulation of angiogenesis" at page 6. Specifically, Applicant submits that "Applicants [...]provided reliable evidence that PRO444 stimulates *c-fos* in pericytes. [...] at the time the application was filed, in was well known that pericytes are involved in angiogenesis. Specifically, studies had shown that pericytes are present in newly formed capillary sprouts, and that pericytes are involved in later stages of angiogenesis, including survival of newly formed vasculature, for example by secretion of VEGF. [Also,] it was well known at the time the application was filed that VEGF is a potent angiogenic factor, and the VEGF expression is regulated by *c-fos*. [Accordingly,] the skilled artisan, like Applicants, would more likely than not believe that PRO444, as a stimulator of *c-fos* in pericytes, would be useful as a therapeutic target for pathological angiogenesis, as well as a tool for stimulating angiogenesis" (bottom at page 6). Applicant's arguments have been carefully considered but are not deemed to be persuasive for the following reasons.

The instant specification discloses structure of a novel polypeptide designated PRO444 of SEQ ID NO: 9 encoded by polynucleotide of SEQ ID NO: 8. The specification further discloses that polypeptide of SEQ ID NO: 9 "act[s] to induce the expression of c-fos in pericyte cells" (page 142, Example 60, assay 93). Based on this finding, the specification asserts that the instant polynucleotides encoding polypeptides of SEQ ID NO: 9 are "useful not only as diagnostic markers for particular types of pericyte-associated tumors but also for giving rise to antagonists

which would be expected to be useful for the therapeutic treatment of pericyte-associated tumors. Induction of c-fos expression in pericytes is also indicative of the induction of angiogenesis and, as such, PRO[444] polypeptides capable of inducing the expression of c-fos would be expected to be useful for the treatment of conditions where induced angiogenesis would be beneficial including, for example, wound healing the like".

As fully explained in the previous office actions of record, PRO444 polynucleotides cannot be used as markers for pericyte-associated tumors because there appears to be no disclosure that PRO444 is exclusively present/absent or expressed at the altered levels in pericyte-associated tumors. Further, the evidence presented in the instant specification as filed is inadequate to support a conclusion that PRO444-induced activation of expression of c-fos in pericytes is specifically related to angiogenesis. Therefore, the Examiner maintained that two of the Applicant's originally presented asserted utilities (as a marker for pericyte-associated tumors and for induction of angiogenesis in wound healing, for example) were not supported by the instant specification, as filed.

Beginning at page 7 of the Response, Applicant submits that at the time of the filing, the role of pericytes in angiogenesis was fully established and refers to articles by Nehls et al., Phodin et al. and Ozerdam et al (the last cited by the Examiner in the previous office action of record). First, it is important to clarify that the Examiner never disputed that pericytes have a role in angiogenesis. Anatomically, as a part of vasculature, pericytes are reasonably expected to play a significant role in formation of new blood vessels or angiogenesis. However, there appears to be no information available at the time of filing regarding their specific role in angiogenesis (see Applicant's cited art). Moreover, information presented in post-filing publication of Ozerdem et

al., 2003, clearly indicates that it is presently not fully understood if stimulation of pericytes results in up-regulation or down-regulation of vascularization (middle at page 8 of the Response). More importantly, the art at the time of invention does no substantiate the nexus between stimulation of c-fos in pericytes and their involvement, positive or negative, in angiogenesis (see specifically Applicant's reasoning on pages 10-11 of the Response).

At page 8 and page 11 of the Response, Applicant reviews articles, which disclose role of VEGF on promoting angiogenesis. The Examiner agrees that the role of angiogenic factor VEGF is well established. There is also no dispute that the art at the time of filing discloses that pericytes could secrete VEGF. However and contrary to Applicant's statement ("*c-fos* stimulates VEGF expression" at page 11 of the Response), there appears to be no evidence of record to show that induction of c-fos in pericytes is directly and specifically associated with expression of VEGF.

Applicant argues at pages 10-11 that because *c-fos* encodes a subunit of the nuclear transcription factor AP-1 and because AP-1 plays a role in the expression of VEGF, then *c-fos* stimulates VEGF expression. Applicant's arguments as well as presented articles by Tischer et al, Shima et al. and Kolch have been fully considered but are not persuasive because the relationship between *c-fos* , AP-1 and VEGF expression is not obvious. Applicant's reasoning lacks support in the specification as originally filed and also in the publications of record because there appears to be no indication that induction of expression of *c-fos* protooncogene that is known to be induced by many cellular stimuli, including growth factors, cytokines, T-cell activators, UV irradiation, hypoxia and PMA (see reasoning in the previous office actions of record and also Orlandi et al., 1996, Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 1675-11680) leads

to stimulation of VEGF expression by means of AP-1 transcription factor. On the contrary, Orlandi et al. publication discloses that, for example, in fibroblasts VEGF expression is unaffected by *c-fos*.

Applicant further refers to the Declaration of Dr. Gerritsen (The Gerritsen Declaration) under 37 CFR 1.132 filed January 31, 2005 and to publications by Ellis et al. , Kirkpatrick and Willett et al. (pages 11-12 of the Response) . The Gerritsen Declaration was considered and answered in full in the previous office action of record. Briefly, the Declaration is insufficient to overcome the instant rejection because it does not provide support for relationship between expression of *c-fos* in pericytes and angiogenesis. With respect to the publications used in discussion on pages 12-13, Applicant is advised that the asserted utility of the claimed invention cannot be relied upon disclosure available after the filing date of the instant specification. It is a matter of law that the specific and substantial credible utility of the claimed invention must be fully disclosed at the time of filing. As such, the instant specification discloses induction of expression of *c-fos* in pericytes treated with polypeptide of SEQ ID NO: 9 but discloses no evidence or sound scientific reasoning to support the asserted utility that polynucleotides encoding polypeptides of SEQ ID NO: 9 could be useful in stimulation of angiogenesis. There is no disclosure found in the instant specification or in the prior art of record that would specifically substantiate the nexus between *c-fos* activation and expression of VEGF in pericytes or between *c-fos* activation in pericytes and angiogenesis.

Applicant's analysis of articles by Sakurai et al. (2002) and Otani et al. (2000) on pages 14-15 of the Response has been fully considered but is not persuasive. Contrary to Applicant's statement that "Sakurai et al. demonstrates that factors that stimulate *c-fos* in pericytes lead to

stimulation of VEGF" (bottom at page 14), information presented in publication of Sakurai et al. fully supports the Examiner's point that activation of *c-fos* is a non-specific immediate cellular response to plurality of different factors. For example, Sakurai et al. describes that expression of *c-fos* mRNA was induced by FCS (fetal calf serum) and various prostaglandins (see Figure 5); however, only PGD_2 affected the expression levels of VEGF mRNA (page 2779). Further, Otani et al. demonstrated that angiotensin II stimulated VEGF expression on pericytes (page 1192), and angiotensin II stimulated *c-fos* expression in pericytes (page 1195). There appears to be no conclusions made in Otani et al. publication to support an assertion that any factor that stimulates *c-fos* expression in pericytes also stimulates expression of VEGF. The Examiner strongly disagrees with Applicant's statement that "those skilled in the art would more likely than not believe that PRO444, as an inducer of *c-fos* in pericytes, would promote angiogenesis" (middle at page 15 of the Response). On the contrary, a skilled artisan, knowing that addition of fetal calf serum causes induction of *c-fos* (see Sakurai et al. above, for example), would readily appreciate that disclosure that PRO444 polypeptides are capable of stimulation of *c-fos* does not provide any meaningful or definitive evidence that PRO444 molecules could be used as therapeutics in treatment of pathological angiogenesis or any other clinical conditions.

The U.S. Court of Appeals for the Federal Circuit recently addressed the utility requirement in the context of a claim to DNA. *See In re Fisher,* 2005 WL 2139421 (Sept. 7, 2005). The *Fisher* court interpreted *Brenner v. Manson*, 383 U.S. 519, 148 USPQ 689 (1966), as rejecting a "de minimis view of utility" 2005 WL 2139421, at *4. The *Fisher* court held that § 101 requires a utility that is both substantial and specific. *Id.* At *5. The court held that disclosing a substantial utility means "show[ing] that an invention is useful to the public as

disclosed in its current form, not that it may be useful at some future date after further research. Simply put, to satisfy the 'substantial' utility requirement, an asserted use must show that the claimed invention has a significant and presently available benefit to the public." *Id.*

Just as in *Fisher* case where the Board reasoned that use of the claimed ESTs for the identification of polymorphisms is not a specific and substantial utility because "[w]ithout knowing any further information in regard to the gene represented by an EST, as here, detection of the presence or absence of a polymorphism provides the barest information in regard to genetic heritage," (*Id.*, slip op. at 15), in the instant case, in view of the absence of clear understanding of the relationship between polypeptide of SEQ ID NO: 9 and activation of *c-fos* and also what effect this might have on angiogenesis, the instant claimed polypeptide PRO444 is suitable only for additional research to identify or reasonably confirm a "real world" context of use.

Therefore, for reasons of record presented in the previous office actions and reasons fully explained above, the instant rejection of claims 40-47, 50-52 and 56-72 is maintained.

Claim Rejections - 35 USC § 112

7. Claims 40-47, 50-52 and 56-72 stand rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a clear asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

8. Claims 40-44 and 56-59 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed,

had possession of the claimed invention for those reasons of record as explained in the previous office actions of record.

To traverse the instant rejection, Applicant presents essentially the same arguments (pages 16-19 of the Response) that were fully considered and answered earlier in appropriate sections of the previous office actions of record.

At pages 19-20, Applicant refers to *In re Wallach* and argues that since the instant specification "disclosed SEQ ID NOs: 8 and 9, and claims nucleic acids which are at least 80% identical to them or nucleic acids which encode them, and which meet the functional limitation of encoding a polypeptide that stimulates *c-fos* in pericytes" (bottom at page 19), then the requirements of 112, first paragraph, written description are met. Applicant's arguments have been fully considered but are not persuasive for the following reasons.

With respect to *In re Wallach* decision, the Examiner fully agrees that listing of every polynucleotide that meets the limitations presented in the claims 40-44 is not required to satisfy written description requirement. However, as fully explained in the previous communications of record, the only two molecular embodiments that are disclosed in the instant specification as originally filed are limited to polynucleotide of SEQ ID NO: 8 and polypeptide of SEQ ID NO: 9. Knowing that stimulation of *c-fos* expression represents a non-specific cellular response (see reasons of record in appropriate sections related to lack of utility of the instant invention), one skilled in the art clearly cannot rely on the assay disclosed in Example 60 of the instant specification (top at page 20 of the Response) to distinguish which molecular embodiments that demonstrate at least 80% structural similarity to the polynucleotide encoding polypeptide of SEQ ID NO: 9 are encompassed by the instant claims. Thus, the instant specification fails to provide

written description of the claimed polynucleotides so that a skilled artisan can envision the detailed chemical structure of what is claimed.

Conclusion

9. No claim is allowed.

10. This is a continuation of applicant's earlier Application No. 10/066,500. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Olga N. Chernyshev whose telephone number is (571) 272-0870. The examiner can normally be reached on 8:00 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet L. Andres can be reached on (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Olga N. Chernyshev, Ph.D.
Primary Examiner
Art Unit 1649

November 16, 2005

Notice of References Cited	Application/Control No. 10/066,500	Applicant(s)/Patent Under Reexamination ASHKENAZI ET AL.	
	Examiner Olga N. Chernyshev	Art Unit 1649	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Orlandi et al., 1996, Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 1675-11680
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
	Application No.	10/066,500
	Filing Date	February 1, 2002
	First Named Inventor	Avi J. Ashkenazi
	Art Unit	1649
(Multiple sheets used when necessary)	Examiner	Chernyshev, Olga
SHEET 1 OF 1	Attorney Docket No.	GNE.3130R1C7

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number *Number - Kind Code (if known)* Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[1]
	1	ALON, et al. "Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity." *Nature Medicine.* 1(10): 1024-1028 (1995).	
	2	BENJAMIN, et al. "Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal." *Proc. Natl. Acad. Sci.* 94: 8761-8766 (1997).	
	3	ELLIS, et al. "Synopsis of Angiogenesis Inhibitors in Oncology." *Oncology.* 16(5), Supplement: 14-22 (2002).	
	4	FERRARA, Napoleone. "The role of vascular endothelial growth factor in pathological angiogenesis." *Breast Cancer Research and Treatment.* 36: 127-137 (1995).	
	5	FIDLER, et al. "Critical Determinants of Neoplastic Angiogenesis." *The Cancer Journal.* 6(Suppl. 3): S225-S236 (2000).	
	6	JANKNECHT, et al. "Signal integration at the c-*fos* promoter." *Carcinogesesis.* 16(3): 443-450 (1995).	
	7	KIRKPATRICK, Peter. "Bevacizumab." *Nature.* Nature Reviews/Drug Discover. Nature Publishing Group. S8-S9 (May 2005).	
	8	KOLCH, et al. "Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis." *Breast Cancer Research and Treatment.* 36: 139-155 (1995).	
	9	NEHLS, et al. "Pericyte involvement in capillary sprouting during angiogenesis in situ." *Cell Tissue Res.* 270: 469-474 (1992).	
	10	RHODIN, et al. "Capillary growth in the mesentery of normal young rats. Intravital video and electron microscope analyses." *J. Submicrosc. Cythol. Pathol.* 21(1): 1-34 (1989).	
	11	Shima, et al. "The Mouse Gene for Vascular Endothelial Growth Factor." *The Journal of Biological Chemistry.* 271(7): 3877-3883 (1996).	
	12	Tischer, et al. "The Human Gene for Vascular Endothelial Growth Factor." *The Journal of Biological Chemistry.* 266(18): 11947-11954 (1991).	
	13	Willett, et al. "Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer." *Nature Medicine.* 10(2): 145-147 (2004).	

2000945 SMA101805

Examiner Signature	Date Considered 11/16/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.

Proc. Natl. Acad. Sci. USA
Vol. 93, pp. 11675–11680, October 1996
Cell Biology

Identification of a c-*fos*-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family

(Fos/cell transformation)

MAURIZIO ORLANDINI, LUCIA MARCONCINI, REBECCA FERRUZZI, AND SALVATORE OLIVIERO*

Dipartimento di Biologia Molecolare Università di Siena, Centro Ricerche IRIS, via Fiorentina 1, 53100 Siena, Italy

Communicated by William J. Rutter, University of California, San Francisco, CA, July 24, 1996 (received for review June 22, 1996)

ABSTRACT **Using a mRNA differential screening of fibroblasts differing for the expression of c-*fos* we isolated a c-*fos*-induced growth factor (FIGF). The deduced protein sequence predicts that the cDNA codes for a new member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family. Northern blot analysis shows that FIGF expression is strongly reduced in c-*fos*-deficient cells. Transfection of exogenous c-*fos* driven by a constitutive promoter restores the FIGF expression in these cells. In contrast, both PDGF and VEGF expression is unaffected by c-*fos*. FIGF is a secreted dimeric protein able to stimulate mitogenic activity in fibroblasts. FIGF overexpression induces morphological alterations in fibroblasts. The cells acquire a spindle-shaped morphology, become more refractive, disorganized, and detach from the plate. These results imply that FIGF is a downstream growth and morphogenic effector of c-*fos*. These results also suggest that the expression of FIGF in response to c-*fos* activation induces specific differentiation patterns and its aberrant activation contributes to the malignant phenotype of tumors.**

The c-*fos* protooncogene plays a central role in the nuclear response to stimulatory signals that regulate cellular proliferation and differentiation. It codes for a nuclear protein that belongs to the AP-1 family of transcription factors. AP-1 factors are part of the bZip family of transcription factors which can form homo- and heterodimers and activate transcription by binding the DNA at AP-1 sites (1, 2). AP-1 is composed of dimeric complexes formed between Jun (c-Jun, JunB, and JunD) and Fos (c-Fos, FosB, Fra1, and Fra2) proteins which are induced by many cellular stimuli including growth factors, citokines, T-cell activators, and UV irradiation (3). As a member of the immediate-early genes, c-*fos* expression is rapidly and transiently increased in response to extracellular signals. The role of c-*fos* during development has been studied by the generation of c-*fos*-deficient mice (4, 5). c-*fos* knockout mice are viable but show a range of tissue specific developmental defects including osteopetrosis, delayed gametogenesis, and limphopenia.

Continuous expression of c-*fos* causes transformation of fibroblasts and loss of polarity of epithelial cells *in vitro* (6), and induces the formation of condroblastic osteosarcomas when it is expressed under the control of ubiquitous promoters in transgenic mice (ref. 7 and references therein). Tumors obtained from c-*fos*-deficient cells fail to undergo malignant progression even if they are carrying the activated v-H-ras (8). These experiments suggest an essential role of c-*fos* in the malignant tumor development. c-*fos* contribution to differentiation and tumor progression is most probably due to the activation of specific target genes. These may play a role in differentiation, in cell transformation, and/or malignant progression of tumors. A large number of genes have been shown to contain functional AP-1 sites in their regulatory regions. These include c-*jun* (2), the adipocyte P2 gene (9), type I collagenase (10), and stromelysin (11). Different strategies have been adopted to identify new c-*fos* target genes. The generation of a hormonally regulated c-Fos-estrogen receptor chimera allowed the isolation of the c-*fos* responsive gene Fit-1 (12) which codes for a membrane-associated protein. Reversion of the v-*fos*-dependent transformed phenotype in rat cells allowed the isolation of Fte-1 (13), a protein probably involved in protein import into mitochondria.

To isolate new c-*fos*-responsive genes we utilized cells differing only for the expression of c-*fos*. By mRNA differential display we compared the expression pattern of c-*fos*-deficient fibroblasts with cells derived from their wild-type siblings. In this report we describe the isolation of a cDNA that is strongly induced by c-*fos*. The cDNA sequence shows that it codes for a putative growth factor related to the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family. The protein, which was named FIGF (for c-*fos*-induced growth factor), is secreted and shows autocrine mitogenic and morphogenic effects on fibroblasts.

MATERIALS AND METHODS

Cells and Cell Culture. c-*fos* (−/−)-deficient fibroblasts, obtained from c-*fos* knockout mice (5, 14) and c-*fos* (+/+) fibroblasts derived from their wild-type siblings were grown in DMEM supplemented with 10% fetal calf serum (FCS). The c-*fos* (−/−)f cells, which express constitutively c-*fos*, were cultured in DMEM supplemented with 10% FCS and G418 (Geneticin; GIBCO/BRL) at 400 μg/ml. Stable clones constitutively expressing FIGF were obtained by cotransfection of an FIGF expression vector together with a plasmid containing the hygromycin resistance gene under the control of the simia virus 40 promoter (SO166). Transfectants were selected in DMEM supplemented with 10% FCS and hygromycin B (Calbiochem) at 300 μg/ml. The FIGF expression vector was constructed by the cloning of the FIGF cDNA under the control of the cytomegalovirus (CMV) promoter in the plasmid pcDNAIII-Δ neo (kindly provided by L. D'Adamio, National Institutes of Health).

Differential Display and Cloning of FIGF cDNA. c-*fos* (−/−) and c-*fos* (+/+) cells were maintained in DMEM containing 0.5% FCS for 48 h and then subjected to serum treatment. After 2 h of 10% serum induction, total cellular

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "*advertisement*" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Abbreviations: PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; FCS, fetal calf serum; CMV, cytomegalovirus; MEF, mouse embryo fibroblast

Data depostion: The sequence reported in this paper has been deposited in the GenBank data base (accession no. U99572).

*To whom reprint requests should be addressed. e-mail oliviero@iris02.biocine.it.

RNA was extracted by the guanidinium thiocyanate method (15) and subjected to the differential display technique (16–18). The amplified cDNA fragments were compared in non-denaturing gels (19). The differentially expressed cDNAs were reamplified, cloned into pGEM-T vector (Promega), and used as probe in Northern blot assay. A fibroblast cDNA library was generated by oligo-dT reverse transcription of poly(A)$^+$ RNA from a cell clone constitutively expressing c-*fos*, and cloned into Uni-Zap vector (Stratagene). A partial cDNA fragment (273 bp), whose corresponding mRNA was induced by c-*fos*, was labeled with [^{32}P]dCTP by random prime labeling and used to screen the library. The longest cDNA isolated was sequenced on both strands by the dideoxy DNA sequencing method (United States Biochemical).

Northern Blot Analysis. Total RNA (10 μg) was run on denaturing formaldehyde-agarose gel and transferred to nylon membranes. Filters were hybridized with [^{32}P]-labeled probes at 60°C in a buffer containing 0.5 M sodium phosphate (pH 7.2), 7% SDS, and 1 mM EDTA. The filters were washed for two 30-min periods at 60°C in 40 mM sodium phosphate (pH 7.2), 1% SDS, and 1 mM EDTA and exposed to x-ray film or analyzed by using a PhosphorImager (Molecular Dynamics).

Production of Bacterial FIGF and Anti-FIGF Antibodies. The FIGF protein was expressed in *Escherichia coli* under the control of the T5 promoter. The cDNA fragment, from the coding region of FIGF, was generated by PCR from the methionine residue at position +40 and cloned into the pQE-31 vector (Qiagen, Chatsworth, CA) to obtain a fusion protein with a N-terminal histidine tag. The protein was expressed in TG1 bacteria (pREP+) by induction for 4 h at 37°C in the presence of 2 mM isopropyl β-D-thiogalactopyranoside. The recombinant protein was exclusively localized in inclusion bodies and was purified on a column of Ni-NTA-resin under denaturing conditions, according to the manufacturer's protocols (Qiagen). To produce partially refolded FIGF protein, the purified recombinant protein was treated as described (20, 21). Briefly the protein concentration was adjusted to 0.4 mg/ml and completely reduced in the presence of 8 M urea, 2% 2-mercaptoethanol for 1 h at 37°C. The reduced protein was dialyzed against a solution containing 50 mM Tris·HCl (pH 8.0), 1 M urea, 5 mM reduced glutathione, and 0.5 mM oxidized glutathione for 2 days, and against a solution containing 20 mM Tris·HCl (pH 7.5) and 0.2 M NaCl for 1 day. Polyclonal antibodies were raised by injecting New Zealand White rabbits with 200 μg of recombinant FIGF in form of denaturated protein in complete Freund's adjuvant. Antiserum was prepared after four injections in incomplete Freund's adjuvant at 3-week intervals.

Expression of FIGF in COS-7 Cells. COS-7 cells were transfected with an expression vector (pcDNAIII; Invitrogen) containing the FIGF coding sequence by using calcium phosphate precipitation. Cells were metabolically labeled with

A

```
1                                                                  50
MYGEWGMGNI LMMFHVYLVQ GFRSEHGPVK DFSFERSSRS MLERSEQQIR

51                                                                 100
AASSLEELLQ IAHSEDWKLW RCRLKLKSLA SMDSRSASHR STRFAATFYD

101                                                                150
TETLKVIDEE WQRTQCSPRE TCVEVASELG KTTNTFFKPP CVNVFRCGGC

151                                                                200
CNEEGVMCMN TSTSYISKQL FEISVPLTSV PELVPVKIAN HTGCKCLPTG

201                                                                250
PRHPYSIIRR SIQTPEEDEC PHSKKLCPID MLWDNTKCKC VLQDETPLPG

251                                                                300
TEDHSYLQEP TLCGPHMTFD EDRCECVCKA PCPGDLIQHP ENCSCFECKE

301                                                                350
SLESCCQKHK IFHPDTCSCE DRCPFHTRTC ASRKPACGKH WRFPKETRAQ

        358
GLYSQENP
```

B

```
FIGF    (103) TLKVIDEEWQ RTQCSPRETC VEVASELGKT T..NTFFKPP CVNVFRCGGC
VEGF-C  (49)  ILKSIDNEWR KTQCMPREVC IDVGKEFGVA T..NTFFKPP CVSVYRCGGC
VEGF    (39)  EVVKFMDVYQ RSYCHPIETL VDIFQEYPDE I..EYIFKPS CVPLMRCGGC
PlGF    (39)  EVVPFQEVWG RSYCRALERL VDVVSEYPSE V..EHMFSPS CVSLLRCTGC
VEGF-B  (35)  VVVPWID.VYA RATCQPREVV VPLSMELMGN V..VKQLVPS CVTVQRCGGC
PDGF-B  (84)  GSLTIAEPAM IAECKTRTEV FEISRRLIDR TNANFLVWPP CVEVQRCSGC
PDGF-A  (83)  RRKRSIEEAV PAVCKTRTVI YEIPRSQVDP TSANFLIWPP CVEVKRCTGC

FIGF    (151) CNEEGVMCMN TSTSYISKQL FEIS.VPLTS VPELVPVKIA NHTGCKCLPT
VEGF-C  (97)  CNSEGLQCMN TSTSYLSKTL FEIT.VPLSQ GPKPVTISFA NHTSCRCMSK
VEGF    (87)  CNDEGLECVP TEESNITMQI MRIK..P.HQ GQHIGEMSFL QHNKCECRPK
PlGF    (87)  CGDENLHCVP VETANVTMQL LKIR..S.GD RPSYVELTFS QHVRCECRPL
VEGF-B  (82)  CPDDGLECVP TGQHQVRMQI LMIQ.YPSSQ ...LGEMSLE EHSQCECRPK
PDGF-B  (134) CNNRNVQCRP TQVQLRPVQV RKIEIVRKKP IFKKATVTLE DHLACKCETV
PDGF-A  (133) CNTSSVKCQP SRVHHRSVKV AKVEYVRKKP KLKEVQVRLE EHLECACATT
```

FIG. 1. (*A*) Deduced amino acid sequence of mouse FIGF. The putative secretory signal peptide rich in hydrophobic residues is underlined. (*B*) Alignment of the FIGF protein with the conserved domain of the PDGF/VEGF family of growth factors. Amino acid residues identical to FIGF are boxed. Dots indicate the cysteine residues which are characteristic of these growth factors (22). Numbers on the left indicate amino acid positions relative to the initiator methionine residue of each protein.

[^{35}S]methionine and [^{35}S]cysteine (Amersham) at 100 mCi/ml (1 Ci = 37 GBq) for 1 h and chased with cold methionine and cysteine. After the chase period medium was collected and cells were lysed in 50 mM Tris·HCl (pH 7.5), 1% Nonidet P-40, 150 mM NaCl, and 4 μg/ml phenylmethylsulfonyl fluoride. Conditioned media and cell lysates were immunoprecipitated separately with anti-FIGF polyclonal antibodies. Immune complexes were collected on protein A-Sepharose beads (Pharmacia) and separated by 12% SDS/PAGE in the presence of 2% 2-mercaptoethanol.

Mitogenic Assay for FIGF. Conditioned medium containing FIGF was collected from cells transfected with the appropriate expression vectors or with vector alone. c-*fos* (−/−) cells were plated into 96-well plates at the density of 5 × 10^3 cells/well in DMEM supplemented with 0.5% FCS and incubated for 48 h. Mouse embryo fibroblasts (MEFs) were obtained from 13- to 15-day embryos of B6D2F1 mice. The embryos were sacrificed, rinsed in Hanks' balanced salt solution and trypsinized for 30 min at 37°C. MEFs were grown in DMEM supplemented with 10% FCS. Second-passage MEFs were plated into 96-well plates at the density of 7 × 10^3 cells/well in DMEM containing 0.5% FCS and incubated for 30 h. Conditioned media or purified proteins were added to the wells and cells were stimulated for 14 h. [^{3}H]Thymidine (2.5 μCi/ml) diluted in DMEM without serum was added to the cells for a period of 8 h. Cells were washed with PBS, trypsinized, and the incorporated radioactivity was determined by liquid scintillation counting.



FIG. 2. (*A*) Expression of FIGF in cultured cells. Northern blot analysis of total RNA obtained from c-*fos* (−/−) fibroblasts, a cell line lacking c-*fos* (lanes 1–3); c-*fos* (−/−)f cells, a stable cell line expressing exogenous c-*fos*, obtained transfecting c-*fos* (−/−) cells with c-*fos* under the control of a constitutive promoter (lanes 4–6); wild-type c-*fos* (+/+) fibroblasts (lanes 7–9). Cellular RNA was extracted from cells grown for 48 h in DMEM supplemented with 0.5% FCS (time 0). The serum concentration was increased to 10% and total RNA was collected at 2 h or 4 h as indicated. Lanes 10 and 11 show FIGF expression in c-*fos* (−/−) fibroblasts transiently transfected with the vector alone (mock) or containing c-*fos* under the control of FBJ–LTR constitutive promoter (c-*fos*). The RNAs of the transiently transfected cells were collected 30 h after culturing the cells in DMEM containing 0.5% FCS. Each lane was loaded with 10 μg of total cellular RNA. (*B*) Expression of PDGF or VEGF in cultured cells. Total cellular RNAs from c-*fos* (−/−) cells (lanes 1–3) or from c-*fos* (−/−)f cells (lanes 4–6) were extracted as indicated in *A*. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control for RNA loading.

RESULTS

Isolation and Characterization of the FIGF cDNA. c-*fos*-deficient cells, derived from c-*fos* knockout mice (5), are defective in the induction of AP-1-responsive genes such as stromelysin and type I collagenase (14). To identify new specific c-*fos* target genes, we used the mRNA differential display technique which allowed us to isolate genes differentially expressed in c-*fos* (−/−) versus wild-type c-*fos* (+/+) cells. Few cDNA fragments, corresponding to differentially expressed mRNA, were identified and their expression pattern was confirmed by Northern blot analysis (data not shown). One of these cDNA fragments was FIGF. The full-length FIGF cDNA was isolated by screening a fibroblast cDNA library using as a probe the cDNA fragment corresponding to the 3′ end of FIGF. The nucleotide sequence of the cDNA revealed a single open reading frame coding for a putative protein of 358-amino acid residues (Fig. 1*A*). FIGF presents a hydrophobic sequence of 20 residues at the N terminus which could code for a signal peptide (23). Comparison of the predicted FIGF protein with the SWISS-PROT data bank revealed a significant similarity of FIGF with the PDGF/VEGF family of growth factors (Fig. 1*B*). FIGF contains, at the same relative distance, the eight conserved cysteine residues which are characteristic of this growth factor's family (22, 24–29). These cysteine residues are involved in intra- and interchain disulfide bridges of the active dimeric molecules (30). The long N-terminal region of FIGF does not show significant similarity to known proteins. The C-terminal domain is very long and rich in cysteine residues, some of which occur in repeat units as described in the recently identified VEGF-C molecule (28).

FIGF Is Induced by c-*fos* in Cultured Fibroblasts. The expression of FIGF transcripts was examined in cells differing for the expression of c-*fos*. Northern blot analysis reveals two hybridizing FIGF transcripts of 2.4 and 4 kbp, respectively. Analysis of FIGF gene expression reveals that the FIGF messenger is barely detectable in c-*fos* (−/−) fibroblasts, while its expression is high in wild-type c-*fos* (+/+) fibroblasts (Fig. 2*A*, compare lanes 1 and 7). FIGF expression is completely restored in stable clones derived from c-*fos* (−/−) cells, expressing exogenous c-*fos* under the control of a constitutive



FIG. 3. Immunoprecipitation assay of the FIGF protein. COS-7 cells transiently transfected with the vector alone (−) or with a vector containing the FIGF coding sequence under the control of a CMV promoter (+) were metabolically labeled. After 1-h or 22-h chase, culture supernatants and detergent-solubilized cell lysates were subjected to immunoprecipitation and SDS/PAGE analysis under reducing conditions. Arrows indicate specific bands present only in FIGF transfected cell. The upper arrow indicates a 66-kDa protein which corresponds to the putative dimer and the lower arrow indicates a 33-kDa protein which corresponds to a putative monomer.

promoter (Fig. 2*A*, compare lanes 1 and 4). To exclude that in c-*fos* (−/−) cells the low expression is due to clonal variation, we transiently transfected these cells with c-*fos* under the control of a constitutive promoter. The transient transfection of exogenous c-*fos*, driven by the viral FBJ-LTR promoter (14), results in FIGF induction in c-*fos* (−/−) cells (Fig. 2*A*, lanes 10 and 11). These experiments show that the FIGF expression is induced by c-*fos*.

Since FIGF shows strong sequence similarities with the PDGF and VEGF, we asked whether their expression was affected by c-*fos*. As can be observed in Fig. 2*B*, the regulation of both PDGF and VEGF transcripts is different from that of FIGF. These growth factors are rapidly induced following serum induction and their expression is independent of c-*fos*. These data indicate that c-*fos* is required for the induction of FIGF, while the c-*fos* expression is not required for the PDGF and VEGF induction. FIGF does not differ from PDGF and VEGF in the negative regulation since they all decrease from 4 h after serum induction (Fig. 2*A*, lanes 6 and 9). Moreover, FIGF mRNA accumulates in quiescent cells. This pattern of expression suggests that, besides the expression of c-*fos*, additional regulatory controls are required for FIGF regulation.

FIGF Is a Secreted Protein. To verify that FIGF is a secreted protein, we transfected COS-7 cells with an expression vector containing the FIGF cDNA under the control of the CMV immediate-early gene promoter. Polyclonal antibodies, raised against recombinant FIGF produced in *E. coli*, immunoprecipitated a specific band that is observed in both the cell lysates and the conditioned media of the FIGF transfected COS-7 cells. After 1-h labeling followed by 1-h chase a specific band was mainly present in the cell lysate (Fig. 3, lane 2) while, after a chase longer than 4 h, the protein accumulated in the cell supernatant (lane 8). Under nondenaturing conditions FIGF aggregated into a multimeric form (not shown). Addition of 2-mercaptoethanol resulted in partial denaturation of the secreted protein which migrated mostly as a 66-kDa band. This corresponds to the migration of the putative dimeric form. Only a minor fraction of the secreted protein can be found at 33 kDa of molecular mass. This should correspond to the expected migration of FIGF in the monomeric form (Fig. 3, lane 8). Dimerization of FIGF could be predicted since the FIGF central domain is highly conserved and contains the eight cysteine residues involved in the dimerization of all the other known members of the PDGF and VEGF family (28–30).



FIG. 4. FIGF induces [³H]thymidine incorporation into fibroblasts. (*A*) Mitogenic activity on c-*fos* (−/−) fibroblasts. Starved cells were stimulated with conditioned medium from COS-7 cells transiently transfected with the FIGF expression vector or with the vector alone (mock). One day after transfection COS-7 cells were split and mantained in 2% serum and conditioned media were collected after 120 h. (*B*) Mitogenic activity on c-*fos* (−/−) fibroblasts. Starved fibroblasts were stimulated with conditioned media obtained from c-*fos* (−/−) stable clones, named FH-10.2, FH-10.5, FH9.3, FH-9.6, FH-10.9, and c-*fos* (−/−) cells (mock), constitutively expressing exogenous FIGF under the control of the CMV promoter. Culture supernatants were collected from cells maintained for 48 h in DMEM supplemented with 0.5% FCS. (*C*) Mitogenic activity induced by the recombinant FIGF protein on c-*fos* (−/−) fibroblasts. Starved cells were incubated with partially renatured recombinant FIGF. Under the same conditions, incubation with PDGF-BB (10 ng/ml; Sigma), used as a positive control, induces about 30% higher [³H]thymidine incorporation, while VEGF (10 ng/ml; Sigma) does not induce incorporation above the background (not shown). The data shown are the mean of six experiments performed with three different FIGF preparations. (*D*) Mitogenic activity on MEFs. Starved MEFs were stimulated with partially renatured recombinant FIGF. Under the same conditions, incubation with PDGF-BB (10 ng/ml; Sigma), used as a positive control, induces about 30% higher [³H]thymidine incorporation, while VEGF (10 ng/ml; Sigma) does not induce incorporation above the background (not shown). The data shown are the mean of six experiments performed with three different FIGF preparations. The background values were subtracted in each experiment.

FIGF Shows Mitogenic Activity on Fibroblasts. The above experiments show that FIGF is a secreted protein. We further investigated whether the conditioned medium of cells producing FIGF could promote cell growth *in vitro*, assayed as [^{3}H]thymidine incorporation. Conditioned medium was obtained either from transiently transfected COS-7 cells or from stable clones, obtained from c-*fos* (−/−) fibroblasts, expressing FIGF under the CMV promoter. The mitogenic activity of the conditioned medium containing FIGF was first tested on c-*fos* (−/−) fibroblasts. Both conditioned medium obtained from transfected COS-7 or constitutive FIGF expressing clones induced DNA synthesis on c-*fos* (−/−) fibroblasts (Fig. 4 *A* and *B*). We also tested the mitogenic activity of the recombinant FIGF protein expressed in *E. coli*. To obtain a biologically active recombinant protein, FIGF was purified from inclusion bodies and partially renatured in the presence of a mixture of reduced and oxidized glutathione. The partially refolded recombinant FIGF-induced DNA synthesis on c-*fos* (−/−) fibroblasts in a dose-dependent manner (Fig. 4*C*). As expected, c-*fos* (−/−) cells were also responsive to PDGF-BB, while the treatment with VEGF did not induce [^{3}H]thymidine incorporation (not shown). We also tested the mitogenic activity of the recombinant FIGF on mouse embryo fibroblasts. As shown in Fig. 4*D*, FIGF-induced DNA synthesis on these cells to levels comparable to those induced by PDGF.



FIG. 5. (*A*) Morphology of c-*fos* (−/−) cells stably transfected with the vector alone. (*B*) Morphology of a cell clone derived from c-*fos* (−/−) cells stably transfected with the expression vector containing FIGF under the control of the CMV promoter. (*C*) Morphology of cells stably transfected with an expression vector containing the FIGF cDNA in the antisense orientation under the control of the CMV promoter. (*D*) Morphology of cells stably transfected with the expression vector containing c-*fos* under the control of the FBJ-LTR promoter. (*E*) A cell clone derived from the same cells as in *D* (expressing c-*fos* contitutively) transfected with an expression vector containing FIGF under the control of the CMV promoter. (*F*) A cell clone derived from the same cells as in *D* (expressing c-*fos* contitutively) transfected with an expression vector containing the FIGF cDNA in the antisense orientation under the control of the CMV promoter. (*G*) c-*fos* (−/−) fibroblasts cultured for 120 h in DME medium containing 0.5% serum. (*H*) Cells as in *G* but treated for 120 h with partially renatured recombinant FIGF at 2 μg/ml. Ten independent clones obtained from three independent transfections were analyzed. All showed morphological changes similar to those observed in the figure.

FIGF Induces Morphological Alterations on Fibroblasts. The induction of transformed foci by v-H-ras, v-src, Polyoma middle T antigen, and simian virus 40 large T is not impaired in c-*fos*-deficient cells (14). Rather, c-*fos* has been implicated in tumor progression (8) and its overexpression induces a transformed cell morphology in fibroblasts and epithelial cells (6). As FIGF codes for a c-*fos*-induced growth factor, we analyzed whether its overexpression could induce a fibroblast's morphological transformation. Several independent clones overexpressing FIGF were isolated and all showed morphological alterations. Fig. 5 shows typical morphological changes observed. Cells overexpressing FIGF acquire a spindle-shaped morphology, become more refractive, and detach from the plate (Fig. 5 *B* versus *A*). The constitutive expression of c-*fos* induces morphological changes in c-*fos*-deficient cells which are similar, although less evident, to the alterations observed with the FIGF overexpression (Fig. 5*D*). The overexpression of both c-*fos* and FIGF leads to the same phenotype determined by FIGF overexpression and cells become extremely long (Fig. 5*E*). The depletion of FIGF, obtained by the expression of FIGF in the antisense orientation in c-*fos* constitutive cells, causes the complete loss of the elongated phenotype (Fig. 5*F*). These data show that FIGF is able to induce morphological changes on fibroblasts and suggest that FIGF is the morphological effector of c-*fos*. Cells expressing the FIGF in the antisense orientation show a slow growth rate (not shown).

To verify whether FIGF induces morphological changes on fibroblasts *in vitro* we also treated c-*fos* (−/−) fibroblasts with recombinant FIGF. As can be observed in Fig. 5*H*, that shows cells treated with recombinant FIGF for 120 h, the cell treatment with recombinant FIGF induces morphological alterations similar to the ones observed with the FIGF overexpression.

DISCUSSION

Nuclear oncogenes contribute to the cancerous state by directly altering gene regulation. The missing link between oncogenes and tumors has been the identification of oncologically relevant genes regulated by oncogenes. Some Fos target genes have already been cloned, but we are still far from understanding their role in tumor progression. To identify c-*fos*-responsive genes we isolated differentially expressed genes in cells differing for the expression of c-*fos*. Here we describe the cloning and characterization of the cDNA coding for the gene referred as FIGF. FIGF codes for a 358 amino acid residues long secreted protein. Its deduced amino acid sequence indicates that FIGF is strongly related to the PDGF/VEGF growth factors. FIGF contains in its central region the signature sequence which is characteristic for this family of growth factors. This region contains eight cysteine residues which are important for dimerization. We provide evidence that FIGF acts as a growth and morphogenic factor on fibroblasts *in vitro*. The mechanism of c-*fos* induction in response to PDGF has been well characterized (31, 32). The finding that a growth factor can be induced by c-*fos* allows to put in a consequential order of activation different growth factors of the PDGF family. Thus, the c-*fos* induction in response to PDGF or other growth stimuli may lead to the induction of other growth factors, FIGF being one of them, which most probably allows the cells to differentiate through a specific pathway.

The FIGF expression pattern analyzed by Northern blot showed a reduced expression of FIGF in c-*fos*-deficient cells. That FIGF low expression is due to the lack of c-*fos* rather than to clonal variations is demonstrated by the restoration of FIGF mRNA upon induction of exogenously expressed c-*fos* in these cells. FIGF is expressed at elevated levels, within 2 h after serum induction. This corresponds to the expression of a c-*fos*-induced gene. However, FIGF transcripts accumulates

during the quiescent phase as well. Thus, the FIGF induction is likely to require other regulatory mechanisms, probably connected with the cell cycle, in addition to the requirement for c-*fos*.

The FIGF pattern of expression differs considerably from the expression of its related genes PDGF and VEGF. These growth factors are induced rapidly after serum stimulation and their expression is not affected by c-*fos*. FIGF pattern of expression is most similar to *gas 6*. This gene, which acts as a growth factor, is abundantly expressed in serum starved cells (33, 34).

The FIGF induction by c-*fos* appears quite specific since c-*fos* cannot be substituted by other AP-1 transcription factors. In fact, in c-*fos*-deficient cells all AP-1 transcription factors except c-*fos* are normally expressed (14). In addition, the transfection of the aspecific AP-1 transcriptional activator GCN4 into these cells fails to induce FIGF (data not shown). In mammalian cells GCN4 is able to activate most AP-1 target genes, but it is nononcogenic (35). Taken together, these observations suggest that FIGF is involved in c-*fos*-dependent cell transformation. c-*fos* does not seem to be necessary for early proliferative steps of tumor formation, but it is required for malignant tumor conversion (8). Therefore FIGF could play a role in tumor progression. In this respect FIGF would not differ from VEGF. VEGF plays a role in tumor angiogenesis (36). It has recently been observed that its mRNA is elevated in papillomas originating from c-*fos* wild-type cells with respect to papillomas originating from c-*fos*-deficient cells (8). This contrasts with our results which demonstrate that, *in vitro*, the VEGF mRNA level is not affected by c-*fos*. It is likely that other events must happen before VEGF is induced during tumor progression since this effect can only be observed *in vivo*.

It has been shown that continuos c-*fos* expression induces morphological transformations *in vitro*. These morphological modifications require at least 24 h of continuous c-*fos* expression (6). We observed that FIGF is induced with a slow kinetics in response to c-*fos* and its overexpression induces morphological transformations in fibroblasts. These morphological alterations are similar to those induced by the overexpression of c-*fos* in fibroblasts. Taken together, these data suggest that FIGF is a mitogenic and morphogenic effector of c-*fos*. Thus, the role of c-*fos* in the activation of the malignant phenotype is due, at least in part, to the induction of FIGF. The involvement of FIGF in tumor progression could represent a promising step toward the therapeutic prevention of neoplastic diseases.

We thank L. D'Adamio, C. Galeotti, and M. L. Melli for the critical reading of the manuscript; B. Grandi for technical assistance; Rino Rappuoli for his precious and continuous suggestions and encouragement; and A. Tramontano for help in computer analysis. This work was supported in part by Associazione Italiana per la Ricerca sul Cancro.

1. Ransone, L. & Verma, I. M. (1990) *Annu. Rev. Cell Biol.* **6**, 539–557.
2. Angel, P. & Karin, M. (1991) *Biochim. Biophys. Acta* **1072**, 129–157.
3. Karin, M. (1995) *J. Biol. Chem.* **270**, 16483–16486.
4. Wang, Z.-Q., Ovitt, C., Gregoriadis, A. E., Möhle-Steinlein, U., Rüther, U. & Wagner, E. F. (1992) *Nature (London)* **360**, 742–745.
5. Johnson, R. S., Spiegelman, B. M. & Papaioannou, V. E. (1992) *Cell* **71**, 577–586.
6. Miao, G. G. & Curran, T. (1994) *Mol. Cell. Biol.* **14**, 4295–4310.
7. Grigoriadis, A. E., Wang, Z.-Q. & Wagner, E. F. (1995) *Trends Genet.* **11**, 436–441.
8. Saez, E., Rutemberg, S. E., Mueller, E., Oppenheim, H., Smoluk, J., Yuspa, S. H. & Spiegelman, B. M. (1995) *Cell* **82**, 721–732.
9. Distel, R., Ro, H. S., Rosen, B. S., Groves, D. & Spiegelman, B. M. (1987) *Cell* **49**, 835–844.
10. Schontal, A., Herrlich, P., Rahmsdorf, H. J. & Ponta, H. (1988) *Cell* **54**, 325–334.
11. Kerr, L. D., Holt, J. T. & Matrisian, L. M. (1988) *Science* **242**, 1424–1427.
12. Superti-Furga, G., Berges, G., Picard, D. & Busslinger, M. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 5114–5118.
13. Kho, C.-J. & Zarbl, H. (1992) *Proc. Natl. Acad. Sci. USA* **89**, 2200–2204.
14. Hu, E., Mueller, E., Oliviero, S., Papaioannou, V., Johnson, R. & Spiegelman, B. (1994) *EMBO J.* **13**, 3094–3103.
15. Chomzyski, P. & Sacchi, N. (1987) *Anal. Biochem.* **162**, 156–159.
16. Liang, P. & Pardee, A. B. (1992) *Science* **257**, 967–971.
17. Liang, P., Averboukl, L. & Pardee, A. B. (1993) *Nucleic Acids Res.* **21**, 3269–3275.
18. Liang, P. & Pardee, A. B. (1995) *Curr. Opin. Immunol.* **7**, 274–280.
19. Bauer, D., Müller, H., Reich, J., Riedel, H., Ahrenickiel, V., Warthoe, P. & Strauss, M. (1993) *Nucleic Acids Res.* **21**, 4272–4280.
20. Hoppe, J., Weilch, H. A., Eichner, W. & Tatje, D. (1990) *Eur. J. Biochem.* **187**, 207–214.
21. Hoppe, J., Weich, H. A. & Eichner, W. (1989) *Biochemistry* **28**, 2956–2960.
22. Betsholds, C., Johnsson, A., Heldin, C.-H., Westermark, B., Lind, P., Urdea, M. S., Eddy, R., Shows, T. B., Philphott, K., Mellor, A. L., Knott, T. J. & Scott, J. (1986) *Nature (London)* **320**, 695–699.
23. von Heijne, G. (1986) *Nucleic Acids Res.* **14**, 4683–4690.
24. Leung, D. W., Cachianes, G., Kuang, W., Goeddel, D. V. & Ferrara, N. (1989) *Science* **246**, 1306–1309.
25. Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J. & Connolly, D. T. (1989) *Science* **246**, 1309–1312.
26. Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. & Persico, M. G. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 9267–9271.
27. Claffey, K. P., Wilkinson, W. O. & Spiegelman, B. M. (1992) *J. Biol. Chem.* **267**, 16317–16322.
28. Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lathinen, I., Kukk, E., Saksela, O., Kalkkinen, N. & Alitalo, K. (1996) *EMBO J.* **15**, 290–298.
29. Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela, O., Orpana, A., Petterson, R. F., Alitalo, K. & Erikson, U. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 2576–2581.
30. Andersson, M., Östman, A., Bächström, G., Hellman, U., George-Nascimento, G., Wastermark, B. & Heldin, C.-H. (1992) *J. Biol. Chem.* **267**, 11260–11266.
31. Wagner, B. J., Hayes, T. E., Hoban, C. J. & Cochran, B. (1990) *EMBO J.* **9**, 4477–4484.
32. Silvennoinen, O., Schindler, C., Schessinger, J. & Levy, D. E. (1993) *Science* **261**, 1736–1738.
33. Manfioletti, G., Brancolini, C., Avanzi, G. & Schneider, G. (1993) *Mol. Cell. Biol.* **13**, 4976–4985.
34. Schneider, C., King, R. M. & Philipson, L. (1988) *Cell* **54**, 787–793.
35. Oliviero, S., Robinson, G., Struhl, K. & Spiegelman, B. M. (1992) *Genes Dev.* **6**, 1799–1809.
36. Kim, K., Li, B., Winer, J., Armanini, M., Gilleet, N., Philips, H. S. & Ferrara, N. (1993) *Nature (London)* **362**, 841–844.